Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16257700 | 0.86 | HPGD (0.56) | HPGDCYP1A2USP2ALDH1A1POLB | |
| Citiolone SCHEMBL364495 | 0.85 | CYP1A2 (0.60) | HPGDCYP1A2USP2ALDH1A1POLB | |
| Citiolone SCHEMBL707846 | 0.85 | CYP1A2 (0.60) | HPGDCYP1A2USP2ALDH1A1POLB | |
| Citiolone SCHEMBL3157776 | 0.83 | CYP1A2 (0.58) | HPGDCYP1A2USP2ALDH1A1POLB | |
| SCHEMBL14521500 | 0.79 | CYP1A2 (0.73) | CYP1A2USP2ALDH1A1POLBMEN1 | |
| SCHEMBL21007472 | 0.79 | CYP1A2 (0.73) | CYP1A2USP2ALDH1A1POLBMEN1 | |
| SCHEMBL15976421 | 0.79 | USP2 (0.63) | CYP1A2USP2POLB | |
| SCHEMBL12505245 | 0.79 | ALDH1A1 (0.62) | CYP1A2USP2ALDH1A1POLBMEN1 | |
| SCHEMBL11256738 | 0.77 | ALDH1A1 (0.56) | CYP1A2USP2ALDH1A1POLBMEN1 | |
| SCHEMBL15185176 | 0.77 | ALDH1A1 (0.56) | CYP1A2USP2ALDH1A1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| EP-1692107-A4 | NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1692107-A2 | NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005060603-A2 | NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | PC, PDK1, NOS3 | HPGD 101/4885CYP1A2 2815/4885USP2 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.